Please login to the form below
Lutathera
This page shows the latest Lutathera news and features for those working in and with pharma, biotech and healthcare.
Novartis raises 2019 guidance as new products gather speed
from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel). ... Meanwhile, Lutathera’s contribution was only $3m more in the second quarter compared to the first three months of the year,
Latest news
-
Alcon spun off, leaner Novartis raises profit forecast
treatments Lutathera ($106m), Promacta ($307m), Kisqali ($91m) and Kymriah ($45m).
-
Novartis aims for 10 blockbuster launches by 2020
Lutathera -Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumours. 2019. BYL719 – advanced breast cancer.
-
Novartis: pipeline will generate 60 filings in three years
The company will also highlight its radioligand portfolio, currently headed by Lutathera (. 177. Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours, which was recently bolstered by the $2.1bn acquisition of
-
Novartis buys cancer specialist Endocyte for $2.1bn
Novartis wants to merge the company with a newly-formed subsidiary that will focus on radiopharmaceutical drugs for cancer, with Endocyte’s portfolio blended with in-house assets such as Lutathera (. ... drugs. Lutathera brought in $56m as it continues
-
AAA board presses go on $3.9bn Novartis takeover
With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
